domestically-made new drug to treat Alzheimer’s disease completed its
phase 3 clinical trial on Tuesday, a breakthrough that marks the most
critical step in the drug development and the last test before entering
The new drug, named “GV-971”, was co-developed by Ocean University of
China, Shanghai Institute of Materia Medica under Chinese Academy of
Sciences and Green Valley Pharmaceutical Co., Ltd, after 21 years’
After the 36-week trial, during which patients took 450 mg of this drug
orally twice a day, the drug was proved to meet the expectation in
improving patients’ cognitive function. Some became literate and were
able to write from illiteracy, showing an obvious effect, according to
the doctor in charge of the clinical trial.
Alzheimer’s disease is an irreversible, progressive brain disorder that
slowly destroys memory, thinking skills, and the ability to carry out
simple tasks. Roughly 48 million people globally have been affected by
it so far.